[go: up one dir, main page]

HUP0400964A3 - A pharmaceutical combination comprising either (s)-2-ethoxy-3 [4-(2-{4-methane sulfonyl oxyphenyl]ethoxy))phenyl]propanoic acid or 3-{4-[2-(4-tert-butoxy carbonylamino phenyl)ethoxy]phenyl}-(s)-2-ethoxy propanoic acid and insulin - Google Patents

A pharmaceutical combination comprising either (s)-2-ethoxy-3 [4-(2-{4-methane sulfonyl oxyphenyl]ethoxy))phenyl]propanoic acid or 3-{4-[2-(4-tert-butoxy carbonylamino phenyl)ethoxy]phenyl}-(s)-2-ethoxy propanoic acid and insulin

Info

Publication number
HUP0400964A3
HUP0400964A3 HU0400964A HUP0400964A HUP0400964A3 HU P0400964 A3 HUP0400964 A3 HU P0400964A3 HU 0400964 A HU0400964 A HU 0400964A HU P0400964 A HUP0400964 A HU P0400964A HU P0400964 A3 HUP0400964 A3 HU P0400964A3
Authority
HU
Hungary
Prior art keywords
ethoxy
phenyl
propanoic acid
insulin
tert
Prior art date
Application number
HU0400964A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HUP0400964A2 publication Critical patent/HUP0400964A2/hu
Publication of HUP0400964A3 publication Critical patent/HUP0400964A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HU0400964A 2001-06-01 2002-05-30 A pharmaceutical combination comprising either (s)-2-ethoxy-3 [4-(2-{4-methane sulfonyl oxyphenyl]ethoxy))phenyl]propanoic acid or 3-{4-[2-(4-tert-butoxy carbonylamino phenyl)ethoxy]phenyl}-(s)-2-ethoxy propanoic acid and insulin HUP0400964A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0101981A SE0101981D0 (sv) 2001-06-01 2001-06-01 Pharmaceutical combination
PCT/SE2002/001037 WO2002096453A1 (en) 2001-06-01 2002-05-30 A pharmaceutical combination comprising either (s)-2-ethoxy-3 [4-(2- {4-methane sulfonyl oxyphenyl} ethoxy)phenyl] propanoic acid or 3-{4-[2- (4-tert-butoxy carbonylamino phenyl) ethoxy] phenyl}-(s)-2-ethoxy propanoic acid and insulin

Publications (2)

Publication Number Publication Date
HUP0400964A2 HUP0400964A2 (hu) 2004-08-30
HUP0400964A3 true HUP0400964A3 (en) 2007-11-28

Family

ID=20284363

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0400964A HUP0400964A3 (en) 2001-06-01 2002-05-30 A pharmaceutical combination comprising either (s)-2-ethoxy-3 [4-(2-{4-methane sulfonyl oxyphenyl]ethoxy))phenyl]propanoic acid or 3-{4-[2-(4-tert-butoxy carbonylamino phenyl)ethoxy]phenyl}-(s)-2-ethoxy propanoic acid and insulin

Country Status (22)

Country Link
US (1) US20040147600A1 (hu)
EP (1) EP1401485A1 (hu)
JP (1) JP2004532873A (hu)
KR (1) KR20040072027A (hu)
CN (1) CN1535155A (hu)
BR (1) BR0210129A (hu)
CA (1) CA2448637A1 (hu)
CO (1) CO5540383A2 (hu)
CZ (1) CZ20033233A3 (hu)
EE (1) EE200300577A (hu)
HU (1) HUP0400964A3 (hu)
IL (1) IL159034A0 (hu)
IS (1) IS7056A (hu)
MX (1) MXPA03011012A (hu)
NO (1) NO20035236D0 (hu)
NZ (1) NZ529812A (hu)
PL (1) PL367704A1 (hu)
RU (1) RU2003136156A (hu)
SE (1) SE0101981D0 (hu)
SK (1) SK14712003A3 (hu)
WO (1) WO2002096453A1 (hu)
ZA (1) ZA200309261B (hu)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1535612T1 (sl) * 2003-11-28 2006-12-31 Merck Sante Sas Zdravljenje hiperurikemije
PE20061041A1 (es) * 2005-01-28 2006-10-12 Lilly Co Eli Formulaciones y regimen de dosificacion para moduladores alfa de ppar
RU2496487C2 (ru) * 2008-05-19 2013-10-27 Нестек С.А. Способы снижения абсорбции липидов у животных

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9801992D0 (sv) * 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
SE9801990D0 (sv) * 1998-06-04 1998-06-04 Astra Ab New 3-aryl propionic acid derivatives and analogs
EP1145717B1 (en) * 2000-04-13 2004-05-12 Pfizer Products Inc. Synergistic effect of glyburide and milrinone

Also Published As

Publication number Publication date
IS7056A (is) 2003-11-28
ZA200309261B (en) 2005-02-28
US20040147600A1 (en) 2004-07-29
SE0101981D0 (sv) 2001-06-01
BR0210129A (pt) 2004-06-08
CA2448637A1 (en) 2002-12-05
KR20040072027A (ko) 2004-08-16
NZ529812A (en) 2006-03-31
WO2002096453A1 (en) 2002-12-05
HUP0400964A2 (hu) 2004-08-30
CO5540383A2 (es) 2005-07-29
MXPA03011012A (es) 2004-02-27
CN1535155A (zh) 2004-10-06
IL159034A0 (en) 2004-05-12
JP2004532873A (ja) 2004-10-28
EE200300577A (et) 2004-02-16
EP1401485A1 (en) 2004-03-31
NO20035236D0 (no) 2003-11-25
CZ20033233A3 (cs) 2004-12-15
SK14712003A3 (sk) 2004-08-03
RU2003136156A (ru) 2005-05-20
PL367704A1 (en) 2005-03-07

Similar Documents

Publication Publication Date Title
DK1870100T3 (da) 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsyre-ethylester-methansulfonat
PL1667964T3 (pl) Kwasy 4-((fenoksyalkilo)tio)-fenoksyoctowe i analogi
EE200200284A (et) (S)-2-etoksü-3-[4-(2-{4-metaansulfonüüloksüfenüül}etoksü)fenüül]propaanhappe peenestatud vorm
EE200200278A (et) (S)-2-etoksü-3-[4-(2-{4-metaansulfonüüloksüfenüül}etoksü)fenüül]propaanhappe kristalne vorm
JP2005528348A5 (hu)
HUP0400964A3 (en) A pharmaceutical combination comprising either (s)-2-ethoxy-3 [4-(2-{4-methane sulfonyl oxyphenyl]ethoxy))phenyl]propanoic acid or 3-{4-[2-(4-tert-butoxy carbonylamino phenyl)ethoxy]phenyl}-(s)-2-ethoxy propanoic acid and insulin
AU2002365626A1 (en) Process for the preparation of (2s)-3-(4-({(4-(aminocarbonyl)-1-piperidinyl)carbonyl}oxy) phenyl)2-{((2s)-4-methyl-2-{(2-(2-methylphenoxy)acetyl)amino}pentanoyl)amino(propanoic acid and intermediates therefore
HUP0400946A3 (en) A pharmaceutical combination comprising either (s)-2-ethoxy-3-[4-(2-{4-methane sulfonyl oxyphenyl}ethoxy) phenyl]propanoic acid or 3-{4-[2-(4-tert-butoxy carbonyl aminophenyl)ethoxy]phenyl}-(s)-2-ethoxy propanoic acid and a biguanide drug
IL159035A0 (en) A pharmaceutical combination comprising either (s) -2-ethoxy-3- [4- (2-{4-methane sulfonyl oxyphenyl}ethoxy) phenyl] propanoic acid or 3- {4- [2- (4-tert-butoxy carbonyl aminophenyl) ethoxy] phenyl}- (s) -2-ethoxy propanoic acid and a sulfonylurea
HK1062527A (en) A pharmaceutical combination comprising either (s)-2-ethoxy-3- [4-(2-{4-methane sulfonyl oxyphenyl} ethoxy) phenyl] propanoic acid or 3-{4-[2-(4-tert-butoxy carbonyl aminophenyl) ethoxy] phenyl} -(s)-2-ethoxy propanoic acid and a sulonylurea
IL164413A0 (en) (2-((-Alkoxy)-phenyl)-cyclopent-1-enyl)aromatic carbo and heterocyclic acid and derivatives
USD563561S1 (en) Dental cassette
AU2034601A (en) Crystalline form of 3-(4-(2-(4-tert-butoxycarbonylaminophenyl)ethoxy)phenyl)-(s) 2-ethoxy propanoic acid
IS8224A (is) Amínsölt (-)-2-{[2-(4-hýdroxýfenýl)etýl]-þíó}-3-[4-(2-{4-[(metýlsúlfónýl)oxý]fenoxý}etýl)fenýl]própansýru og notkun þeirra í læknisfræði
NO20000665D0 (no) 2-{3-[4-(2-t-Butyl-6-trifluormetyl-4-pyrimidinyl)-1- piperazinyl]propyltio}-4-pyrimidinol-fumarat
SI1260505T1 (en) A process for the preparation of 4-(1-hydroxy-4-(4-(hydroxydiphenylmethyl)-1-piperidinyl)-butyl)-alpha, alpha-dimethylbenzeneacetic acid
AU2003244922A1 (en) 4-(4-methylpiperazin-1-ylmethyl)-n-(4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl)-benzamide for treating pulmonary fibrosis
IL162405A (en) Process for preparing 2-(substituted phenyl)-2-hydroxyethyl carbamates and intermediates thereof
AU2003237394A8 (en) Crystalline (2-(4-((4-chlorophenyl)-phenyl methyl)-1-piperazinyl) ethoxy) acetic acid dihydrochloride
HK1087395A (en) Process for the preparation of racemic 2-{[2-(4-hydroxyphenyl)ethyl]thio} -3-{4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenyl]-propanoic acid
HK1087690A (en) Amine salts of (-)-2-{'2-(4-hydroxyphenyl) ethyl!-thio}-3-'4-(2-{4-'(methylsulfonyl)oxy!phenoxy}ethyl)phenyl! propanoic acid and their use in medicine
AU2003228011A1 (en) 2-(2-(4-((4-chlorophenyl) phenylmethyl)-1-piperazinyl)ethoxy)acetic acid monohydrochloride as anti-allergenic compound and process for its production
AU2003201145A1 (en) N-(4-substituted phenyl)-anthranilic acid hydroxamate esters

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees